Shopping Cart
- Remove All
- Your shopping cart is currently empty
AZ-1355 is a novel dibenzoxepine derivative with lipid-lowering properties.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $179 | In Stock | |
5 mg | $438 | In Stock | |
10 mg | $591 | In Stock | |
25 mg | $892 | In Stock | |
50 mg | $1,220 | In Stock | |
100 mg | $1,590 | In Stock | |
200 mg | $2,180 | In Stock | |
1 mL x 10 mM (in DMSO) | $396 | In Stock |
Description | AZ-1355 is a novel dibenzoxepine derivative with lipid-lowering properties. |
In vivo | AZ-1355 consistently decreases serum total cholesterol (TC) in Triton-induced hyperlipidemic mice at a dose of 150 mg/kg. At a lower dose of 50 mg/kg, it significantly lowers serum triglycerides (TG), while a 100 mg/kg dose effectively reduces both serum TC and TG in rats. Additionally, the 100 mg/kg dosage diminishes total liver TC in rats consuming a CE-2 diet, and a 50 mg/kg dose not only reduces liver TC in rats on a high-fat diet but also decreases total hepatic TG in CE-2 fed rats[1]. |
Cell Research | The lipid-lowering profile in rodents AZ-1355, A New Dibenzoxazepine Derivative |
Animal Research | AZ-1355 (150 mg/kg) reproducibly lowers serum total cholesterol (TC) in the Triton hyperlipidemic mice. AZ-1355 (50 mg/kg) significantly reduces serum TG and the 100 mg/kg dose results in serum TC and TG reduction in rats. AZ-1355 (100 mg/kg) reduces total liver TC in rats fed CE-2, and the 50 mg/kg dose reduces hepatic TC in rats fed the high-fat diet on both bases, and it also reduces the total hepatic TG of the CE-2 fed rats. |
Molecular Weight | 299.32 |
Formula | C17H17NO4 |
Cas No. | 75451-07-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 22.5 mg/mL (75.17 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.